Co-Diagnostics Inc
$ 2.35
-0.21%
11 Feb - close price
- Market Cap 4,755,700 USD
- Current Price $ 2.35
- High / Low $ 2.35 / 2.26
- Stock P/E N/A
- Book Value 24.82
- EPS -29.40
- Next Earning Report 2026-03-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.38 %
- ROE -0.62 %
- 52 Week High 46.50
- 52 Week Low 2.20
About
Co-Diagnostics, Inc., a molecular diagnostic company, develops, manufactures, and sells reagents used for diagnostic tests that function by detecting and / or analyzing nucleic acid molecules. The company is headquartered in Salt Lake City, Utah.
Analyst Target Price
$45.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-14 | 2025-05-07 | 2025-03-12 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-14 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-16 |
| Reported EPS | -0.16 | -0.23 | -0.2574 | -0.3778 | -0.32 | -0.14 | -0.31 | -0.5 | -0.2 | -0.31 | -0.2 | -0.68 |
| Estimated EPS | -0.16 | -0.66 | -0.33 | -0.34 | -0.33 | -0.34 | -0.21 | -0.2 | -0.29 | -0.24 | -0.22 | -0.15 |
| Surprise | 0 | 0.43 | 0.0726 | -0.0378 | 0.01 | 0.2 | -0.1 | -0.3 | 0.09 | -0.07 | 0.02 | -0.53 |
| Surprise Percentage | 0% | 65.1515% | 22% | -11.1176% | 3.0303% | 58.8235% | -47.619% | -150% | 31.0345% | -29.1667% | 9.0909% | -353.3333% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CODX
2026-02-09 13:59:10
Co-Diagnostics, Inc. announced its participation in the World Health Expo Labs Dubai from February 10-13, 2026, where it will showcase its Co-Dx PCR platform. This follows the formation of its joint venture, CoMira Diagnostics, in Saudi Arabia, aimed at expanding access to molecular diagnostics in the Middle East and North Africa. The company's PCR platform is currently undergoing clinical studies in the United States and is not yet available for sale, pending regulatory review.
2026-02-09 13:59:10
Co-Diagnostics (OTC: CODX) is set to exhibit its Co-Dx PCR platform at the World Health Expo Labs Dubai from February 10–13, 2026. This participation follows the formation of CoMira Diagnostics, a joint venture aimed at localizing manufacturing and distribution across Saudi Arabia and 18 other MENA countries. The event offers Co-Dx an opportunity to engage with regional stakeholders and advance its strategy to expand access to high-quality molecular diagnostics in the Middle East and North Africa.
2026-02-05 14:30:21
Co-Diagnostics' joint venture, CoSara Diagnostics Pvt. Ltd., has secured a license from the Central Drugs Standard Control Organization (CDSCO) to manufacture and sell the CoSara PCR Pro™ real-time PCR point-of-care instrument in its Ranoli, India facility. This license is a crucial step towards commercializing the PCR Pro instrument and facilitating future regulatory clearance for CoSara PCR test kits for diseases like Mycobacterium tuberculosis (MTB) and human papillomavirus (HPV). The collaboration aims to increase the accessibility of gold-standard PCR diagnostics in underserved areas.
2026-02-05 09:00:00
Co-Diagnostics, Inc.'s joint venture, CoSara Diagnostics Pvt. Ltd., has received a CDSCO license to manufacture and sell the CoSara PCR Pro™ real-time PCR point-of-care instrument in India. This license allows CoSara to produce the device at its Ranoli facility for distribution, marking a crucial step towards commercialization for its decentralized PCR testing platform. The move aims to increase access to gold-standard PCR diagnostics in underserved areas, though associated test kits for MTB and HPV still require separate regulatory clearance.
2026-02-04 09:00:00
Co-Diagnostics, Inc.'s joint venture, CoSara Diagnostics Pvt. Ltd., has achieved ISO 13485:2016 certification for its manufacturing facility in Vadodara, India. This certification is a crucial step for securing regulatory clearance for their upcoming PCR platform and other medical devices, facilitating market access and enhancing stakeholder trust. The achievement is expected to support the "Make in India" initiative, offering cost-saving advantages for manufacturing instruments and test kits within the country.
2026-01-23 18:57:50
Maxim Group has downgraded Co-Diagnostics (CODX) from "Buy" to "Hold," reflecting a more cautious analyst sentiment. This follows previous rating changes, including a significant price target reduction by D. Boral Capital in September 2025. Despite an average analyst target price indicating substantial upside, GuruFocus estimates a downside for CODX based on its GF Value.
